U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C34H41N7O5
Molecular Weight 627.7332
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DABIGATRAN ETEXILATE

SMILES

CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)N2C)C=C1

InChI

InChIKey=KSGXQBZTULBEEQ-UHFFFAOYSA-N
InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)

HIDE SMILES / InChI

Molecular Formula C34H41N7O5
Molecular Weight 627.7332
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s007lbl.pdf https://www.pradaxa.com/

Dabigatran (Pradaxa, Prazaxa) is an anticoagulant medication that can be taken by mouth. FDA approved on October 19, 2010. Dabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results in a prolongation of aPTT (partial thromboplastin time), ECT (Ecarin clotting time), and TT (thrombin time). It may increase INR but this laboratory parameter is relatively insensitive to the activity of dabigatran. Dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL < 30 ml/min); haemorrhagic manifestations, bleeding diathesis or spontaneous or pharmacologic impairment of haemostasis; lesions at risk of clinically significant bleeding (e.g. extensive cerebral infarction (haemorrhagic or ischemic) in the last 6 months, active peptic ulcer disease); concomitant treatment with P-glycoprotein inhibitors (e.g. oral ketoconazole, verapamil); and those with known hypersensitivity to dabigatran, dabigatran etexilate or any ingredient used in the formulation or component of the container. As of December 2012, dabigatran is contraindicated in patients with mechanical prosthetic heart valves.

CNS Activity

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
PRADAXA

Approved Use

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery

Launch Date

2010
Primary
PRADAXA

Approved Use

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery

Launch Date

2010
Preventing
PRADAXA

Approved Use

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery

Launch Date

2010
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
348 ng/mL
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2232 ng × h/mL
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.3 h
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 3 times / day single, oral
Highest studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: single
Dose: 400 mg, 3 times / day
Sources:
healthy, 18–45
Health Status: healthy
Age Group: 18–45
Sex: M
Sources:
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, 18–45
Health Status: healthy
Age Group: 18–45
Sex: M
Sources:
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources:
healthy, 18–45
Health Status: healthy
Age Group: 18–45
Sex: M+F
Sources:
Disc. AE: C-reactive protein increased, Alanine aminotransferase increase...
AEs leading to
discontinuation/dose reduction:
C-reactive protein increased (7.14%)
Alanine aminotransferase increase (7.14%)
Haematuria (7.14%)
Epistaxis (7.14%)
Haemorrhoidal haemorrhage (7.14%)
Sources:
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
unhealthy
Disc. AE: Spinal epidural hematoma, Bleeding...
AEs leading to
discontinuation/dose reduction:
Spinal epidural hematoma
Bleeding (grade 3-5)
Sources:
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
unhealthy
Disc. AE: Bleeding, Gastrointestinal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Bleeding
Gastrointestinal disorder NOS
Sources:
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
unhealthy
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (grade 5, 0.07%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Alanine aminotransferase increase 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources:
healthy, 18–45
Health Status: healthy
Age Group: 18–45
Sex: M+F
Sources:
C-reactive protein increased 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources:
healthy, 18–45
Health Status: healthy
Age Group: 18–45
Sex: M+F
Sources:
Epistaxis 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources:
healthy, 18–45
Health Status: healthy
Age Group: 18–45
Sex: M+F
Sources:
Haematuria 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources:
healthy, 18–45
Health Status: healthy
Age Group: 18–45
Sex: M+F
Sources:
Haemorrhoidal haemorrhage 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources:
healthy, 18–45
Health Status: healthy
Age Group: 18–45
Sex: M+F
Sources:
Spinal epidural hematoma Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
unhealthy
Bleeding grade 3-5
Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
unhealthy
Bleeding Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
unhealthy
Gastrointestinal disorder NOS Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
unhealthy
Bleeding grade 5, 0.07%
Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
unhealthy
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no
no
no
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no (co-administration study)
Comment: Coadministration of Atorvastatin (CYP3A4 & P-gp inhibitor, 400 mg QD x 4 days) with Dabigatran metexilate mesylate (150 mg BID x 3 days and 150 mg QD on Day 4) decreased total Dabigatran AUCtau,ss by 58% and Cmax,ss by 50%., Coadministration of Clarithromycin (CYP3A4 & P-gp inhibitor, 500 mg BID x 5 days & 500 mg QD on Day 6) with Dabigatran metexilate mesylate (150 mg QD on Day 6) increased total Dabigatran AUCinf by 19% and Cmax by 15%., Coadministration of Rifampicin (CYP3A4 & P-gp inducer, 600 mg QD x 7 days in the night) with Dabigatran metexilate mesylate (150 mg QD on Day 8 morning) decreased total Dabigatran AUCinf by 67% and Cmax by 66%., Coadministration of Ketoconazole (CYP3A4 & P-gp inhibitor, 400mg QD ) with Dabigatran metexilate mesylate (150 mg QD) increased total Dabigatran AUCinf by 138% and Cmax by 135%.
Page: (ClinPharm) 13, (PMDA_A100_1 Japanese) 32, 40-41, (PMDA_I100_1 Japanese) 33
no
no (co-administration study)
Comment: Caco-2 cells, Efflux ratio = 1.09 (3 mcM), 0.95 (300 mcM); MDR1-LLC-PK1 cells, Efflux ratio = 1.35 (10 mcM); Coadministration of Amiodarone (P-gp & CYP2C9 inhibitor, 600 mg QD on Day 4) with Dabigatran metexilate mesylate (150 mg BID x 3 days and 150 mg QD on Day 4) increased total Dabigatran AUCtau,ss by 58% and Cmax by 50%., Coadministration of Verapamil (P-gp inhibitor, 120 mg single or multiple doses, or 240 mg single dose) with Dabigatran metexilate mesylate (150 mg single dose) increased total Dabigatran AUCinf by 39~143% and Cmax by 12~179%., Coadministration of Quinidine (200 mg every 2 hr x 5 on Day 3 (3 hr after the first Dabigatran dose), P-gp inhibitor) with Dabigatran metexilate mesylate (150 mg BID x 3 days (2nd dose on Day 3 was administrated 1 hr after the final Quinidine dose) increased total Dabigatran AUCtau,ss by 53% and Cmax,ss by 56%., Coadministration of Ketoconazole (CYP3A4 & P-gp inhibitor, 400mg QD ) with Dabigatran metexilate mesylate (150 mg QD) increased total Dabigatran AUCinf by 138% and Cmax by 135%., Coadministration of Atorvastatin (CYP3A4 & P-gp inhibitor, 400 mg QD x 4 days) with Dabigatran metexilate mesylate (150 mg BID x 3 days and 150 mg QD on Day 4) decreased total Dabigatran AUCtau,ss by 58% and Cmax,ss by 50%., Coadministration of Clarithromycin (CYP3A4 & P-gp inhibitor, 500 mg BID x 5 days & 500 mg QD on Day 6) with Dabigatran metexilate mesylate (150 mg QD on Day 6) increased total Dabigatran AUCinf by 19% and Cmax by 15%., Coadministration of Rifampicin (CYP3A4 & P-gp inducer, 600 mg QD x 7 days in the night) with Dabigatran metexilate mesylate (150 mg QD on Day 8 morning) decreased total Dabigatran AUCinf by 67% and Cmax by 66%.
Page: 54-55, 56-57, (ClinPharm) 12, 13, 33-36, (PMDA_A100_1 Japanese) 33, 39, 40-41, (PMDA_I100_1 Japanese) 66, (PMDA_K103_1 Japanese) 152-156
yes [Km 371.4 uM]
yes [Km 511.7 uM]
yes [Km 987.3 uM]
Tox targets
PubMed

PubMed

TitleDatePubMed
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
2005 May
Emerging anticoagulants: mechanism of action and future potential.
2006 Mar
[Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors].
2006 Nov
[New antitoagulants].
2007 Mar
Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.
2007 Mar
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
2008
Advancement in antithrombotics for stroke prevention in atrial fibrillation.
2008 Aug
Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.
2009 Aug
Recent developments in the use of oral anticoagulants.
2009 Aug
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
2009 Aug
Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT.
2009 Dec
[New oral anticoagulants. Consequences for perioperative coagulation diagnostics and therapy].
2009 Dec
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
2009 Jan
New anticoagulants: focus on venous thromboembolism.
2009 Jul
Dabigatran: new drug. Continue to use heparin, a better-known option.
2009 Jun
[Venous thromboembolism prophylaxis in orthopaedics and traumatology].
2009 Mar
The prevention of hospital-acquired venous thromboembolism in the United Kingdom.
2009 Mar
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
2010 Feb
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
2010 Mar
[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].
2010 Sep
Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
2012 Apr 26
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:29:43 GMT 2025
Edited
by admin
on Mon Mar 31 18:29:43 GMT 2025
Record UNII
2E18WX195X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRADAXA
Preferred Name English
DABIGATRAN ETEXILATE
INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
DABIGATRAN ETEXILATE [MART.]
Common Name English
BIBR-1048
Code English
DABIGATRAN ETEXILATE [VANDF]
Common Name English
PRADAXA (DABIGATRAN ETEXILATE)
Common Name English
dabigatran etexilate [INN]
Common Name English
BIBR1048
Code English
ETHYL 3-(((2-(((4-((((HEXYLOXY)CARBONYL)AMINO)IMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)(PYRIDIN-2-YL)AMINO)PROPANOATE
Systematic Name English
Dabigatran etexilate [WHO-DD]
Common Name English
.BETA.-ALANINE, N-((2-(((4-((((HEXYLOXY)CARBONYL)AMINO)IMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-, ETHYL ESTER
Common Name English
BIBR 1048 BS RS1
Code English
PRAZAXA
Brand Name English
DABIGATRAN ETEXILATE METHANESULFONATE [JAN]
Common Name English
DABIGATRAN ETEXILATE [MI]
Common Name English
DABIGATRAN ETEXILATE [USAN]
Common Name English
BIBR-1048-BS-RS1
Code English
Ethyl 3-{[(2-{[(4-{[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl](pyridin-2-yl)amino}propanoate
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C263
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
WHO-VATC QB01AE07
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
WHO-ATC B01AE07
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
Code System Code Type Description
CHEBI
70743
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
DAILYMED
2E18WX195X
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
DRUG BANK
DB06695
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
PUBCHEM
213023
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
EVMPD
SUB20521
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
CAS
211915-06-9
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
MERCK INDEX
m4064
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY Merck Index
SMS_ID
100000089553
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
RXCUI
1037042
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY RxNorm
DRUG CENTRAL
776
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
ChEMBL
CHEMBL539697
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
USAN
UU-126
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
EPA CompTox
DTXSID4057681
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
INN
8028
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
NCI_THESAURUS
C87480
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
CHEBI
70746
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
IUPHAR
6379
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
FDA UNII
2E18WX195X
Created by admin on Mon Mar 31 18:29:43 GMT 2025 , Edited by admin on Mon Mar 31 18:29:43 GMT 2025
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA; URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA
Related Record Type Details
ACTIVE MOIETY